Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 17/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16636682 | 0.76 | ALDH1A1 (0.45) | HDAC1HDAC6HDAC4ALDH1A1CYP1A2 | |
| SCHEMBL16636602 | 0.75 | ALDH1A1 (0.41) | HDAC1HDAC6HDAC4ALDH1A1CYP1A2 | |
| SCHEMBL18508361 | 0.74 | HDAC1 (0.69) | HDAC1HDAC3HDAC6HDAC4 | |
| SCHEMBL16636990 | 0.73 | ALDH1A1 (0.42) | HDAC1HDAC6HDAC4ALDH1A1CYP1A2 | |
| SCHEMBL26684216 | 0.73 | ALDH1A1 (0.48) | ALDH1A1CYP1A2FBP1 | |
| SCHEMBL16636619 | 0.72 | HDAC4 (0.43) | HDAC1HDAC6HDAC4ALDH1A1CYP1A2 | |
| SCHEMBL29129336 | 0.70 | ALDH1A1 (0.45) | ALDH1A1CYP1A2FBP1 | |
| SCHEMBL3587397 | 0.67 | ALDH1A1 (0.72) | ALDH1A1CYP1A2 | |
| SCHEMBL29129368 | 0.65 | ALDH1A1 (0.43) | ALDH1A1CYP1A2 | |
| SCHEMBL5742872 | 0.64 | NOS1 (0.48) | ALDH1A1CYP1A2FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647731-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3415519-A1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2018-12-19 | — | — | EP | disclosed |
| US-20180244694-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-08-30 | — | — | US | disclosed |
| EP-3055315-B1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2018-07-25 | — | — | EP | disclosed |
| US-9988400-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| EP-3055315-A1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2016-08-17 | — | — | EP | disclosed |
| US-20160222033-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| WO-2015052226-A1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647731-B2 | Thiazolopyrimidinones and methods of use thereof | TPMT, THPO, CYP11B2 | HDAC1 982/4885HDAC3 389/4885HDAC6 160/4885 |
| US-20180244694-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | TPMT, THPO, CYP11B2 | HDAC1 982/4885HDAC3 389/4885HDAC6 160/4885 |
| US-20160222033-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | TPMT, THPO, CYP11B2 | HDAC1 982/4885HDAC3 389/4885HDAC6 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.